Global Exosome Therapeutic Market - Industry Trends and Forecast to 2026
- DAT3384291
- 245 Pages
- November 2019
- Medical Devices
Market Segmentation:
Global Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of Administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Geography (North America, Europe, Asia-Pacific and Latin America)
Some of the major factors contributing to the growth of the market:
• Increasing prevalence of Lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases
• Increasing demand for anti-aging therapy’s
Market Players:
The key market players for global exosome therapeutic market are listed below:
• evox THERAPEUTICS
• EXOCOBIO
• Exopharm
• AEGLE Therapeutics
• United Therapeutics Corporation
• Codiak BioSciences
• Jazz Pharmaceuticals, Inc.
• Boehringer Ingelheim International GmbH
• ReNeuron Group plc
• Capricor Therapeutics
• Avalon Globocare Corp.
• CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC.
• Stem Cells Group
1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.3 OVERVIEW OF GLOBAL EXOSOME THERAPEUTIC MARKET 29
1.4 LIMITATIONS 31
1.5 MARKETS COVERED 31
2 MARKET SEGMENTATION 33
2.1 MARKETS COVERED 33
2.2 GEOGRAPHICAL SCOPE 34
2.3 YEARS CONSIDERED FOR THE STUDY 35
2.4 CURRENCY AND PRICING 35
2.5 DBMR TRIPOD DATA VALIDATION MODEL 36
2.6 MULTIVARIATE MODELLING 39
2.7 PRODUCTS LIFELINE CURVE 39
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 40
2.9 SECONDARY SOURCES 41
2.10 ASSUMPTIONS 41
3 MARKET OVERVIEW 42
3.1 DRIVERS 44
3.1.1 INCREASING PREVALENCE OF LYME DISEASE, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE AND OTHER CHRONIC DEGENERATIVE DISEASES 44
3.1.2 INCREASING DEMAND FOR ANTI-AGING THERAPY’S 47
3.2 RESTRAINT 50
3.2.1 UNMET MEDICAL NEEDS 50
3.3 OPPORTUNITIES 51
3.3.1 PROGRESSING THERAPEUTIC VALUE OF EXOSOME 51
3.3.2 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES 52
3.3.3 TECHNOLOGICAL ADVANCEMENTS IN EXOSOME 55
3.3.4 STRATEGIC RESEARCH INITIATIVES BY MARKET PLAYERS 56
3.3.5 RISING HEALTHCARE INFRASTRUCTURE 57
3.4 CHALLENGE 59
3.4.1 LACK OF SKILLED PROFESSIONAL’S REQUIRED FOR THE ISOLATION OF EXOSOME 59
4 EXECUTIVE SUMMARY 60
5 PREMIUM INSIGHTS 64
6 PIPELINE 66
7 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TYPE 67
7.1 OVERVIEW 68
7.2 HYBRID EXOSOMES 70
7.3 NATURAL EXOSOMES 70
7.3.1 AUTOLOGOUS EXOSOMES 71
7.3.2 EXOGENOUS EXOSOMES 71
8 GLOBAL EXOSOME THERAPEUTIC MARKET, BY SOURCE 72
8.1 OVERVIEW 73
8.2 MESENCHYMAL STEM CELLS 75
8.3 DENDRITIC CELLS 76
8.4 BLOOD 76
8.4.1 B LYMPHOCYTES 77
8.4.2 OTHERS 77
8.5 BODY FLUIDS 77
8.5.1 SYNOVIAL FLUID 78
8.5.2 AMNIOTIC FLUID 78
8.5.3 SEMEN 78
8.5.4 OTHERS 78
8.6 MILK 78
8.7 SALIVA 79
8.8 URINE 79
8.9 OTHERS 80
9 GLOBAL EXOSOME THERAPEUTIC MARKET, BY THERAPY 81
9.1 OVERVIEW 82
9.2 CHEMOTHERAPY 84
9.3 IMMUNOTHERAPY 84
9.4 GENE THERAPY 85
10 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY 86
10.1 OVERVIEW 87
10.2 BIO MACROMOLECULES 89
10.2.1 NUCLEIC ACIDS 90
10.2.2 PEPTIDES 90
10.2.3 PROTEINS 90
10.3 SMALL MOLECULES 90
11 GLOBAL EXOSOME THERAPEUTIC MARKET, BY APPLICATION 91
11.1 OVERVIEW 92
11.2 ONCOLOGY 94
11.2.1 NON-SMALL CELL LUNG CANCER 95
11.2.2 BREAST CANCER 95
11.2.3 GASTRIC CANCER 95
11.2.4 HEAD AND NECK CANCER 95
11.2.5 OTHERS 95
11.3 CARDIAC DISORDERS 96
11.4 METABOLIC DISORDERS 96
11.5 NEUROLOGY 97
11.5.1 PARKINSON'S DISEASE 97
11.5.2 ALZHEIMER'S DISEASE 97
11.5.3 OTHERS 97
11.6 BLOOD DISORDERS 98
11.7 GYNECOLOGY DISORDERS 98
11.8 INFLAMMATORY DISORDERS 99
11.9 ORGAN TRANSPLANTATION 99
11.10 OTHERS 100
12 GLOBAL EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION 101
12.1 OVERVIEW 102
12.2 PARENTERAL 104
12.3 ORAL 104
13 GLOBAL EXOSOME THERAPEUTIC MARKET, BY END USER 105
13.1 OVERVIEW 106
13.2 HOSPITALS 108
13.3 RESEARCH & ACADEMIC INSTITUTES 108
13.4 DIAGNOSTIC CENTERS 109
14 GLOBAL EXOSOME THERAPEUTIC MARKET, BY GEOGRAPHY 110
14.1 OVERVIEW 111
14.2 NORTH AMERICA 116
14.2.1 U.S. 123
14.2.2 MEXICO 127
14.3 ASIA-PACIFIC 131
14.3.1 SOUTH KOREA 138
14.3.2 HONG KONG 142
14.3.3 AUSTRALIA 146
14.4 LATIN AMERICA 150
14.4.1 ARGENTINA 158
14.4.2 COLOMBIA 162
14.4.3 PERU 166
14.4.4 CHILE 170
14.4.5 ECUADOR 174
14.4.6 VENEZUELA 178
14.4.7 PANAMA 182
14.4.8 DOMINICAN REPUBLIC 186
14.4.9 EL SALVADOR 190
14.4.10 PARAGUAY 194
14.4.11 COSTA RICA 198
14.4.12 PUERTO RICO 202
14.4.13 NICARAGUA 206
14.4.14 URUGUAY 210
14.5 TURKEY 214
15 GLOBAL EXOSOME THERAPEUTIC MARKET, COMPANY LANDSCAPE 218
15.1 COMPANY SHARE ANALYSIS: GLOBAL 218
16 COMPANY PROFILE 219
16.1 STEM CELLS GROUP 219
16.1.1 COMPANY SNAPSHOT 219
16.1.2 PRODUCT PORTFOLIO 219
16.1.3 RECENT DEVELOPMENT 219
16.2 EXOCOBIO 220
16.2.1 COMPANY SNAPSHOT 220
16.2.2 PRODUCT PORTFOLIO 220
16.2.3 RECENT DEVELOPMENT 220
16.3 AEGLE THERPEUTICS 221
16.3.1 COMPANY SNAPSHOT 221
16.3.2 PIPELINE PORTFOLIO 221
16.4 AVALON GLOBOCARE CORP. 222
16.4.1 COMPANY SNAPSHOT 222
16.4.2 REVENUE ANALYSIS 222
16.4.3 PIPELINE PORTFOLIO 223
16.4.4 RECENT DEVELOPMENT 223
16.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 224
16.5.1 COMPANY SNAPSHOT 224
16.5.2 REVENUE ANALYSIS 224
16.5.3 PRODUCT PORTFOLIO 225
16.5.4 RECENT DEVELOPMENT 225
16.6 CAPRICOR THERAPEUTICS 226
16.6.1 COMPANY SNAPSHOT 226
16.6.2 PRODUCT PORTFOLIO 226
16.6.3 RECENT DEVELOPMENTS 226
16.7 CODIAK BIOSCIENCES 228
16.7.1 COMPANY SNAPSHOT 228
16.7.2 PIPELINE PORTFOLIO 228
16.7.3 RECENT DEVELOPMENTS 229
16.8 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. 230
16.8.1 COMPANY SNAPSHOT 230
16.8.2 REVENUE ANALYSIS 230
16.8.3 PIPELINE PORTFOLIO 231
16.8.4 RECENT DEVELOPMENT 231
16.9 EXOPHARM 232
16.9.1 COMPANY SNAPSHOT 232
16.9.2 REVENUE ANALYSIS 232
16.9.3 PIPELINE PORTFOLIO 233
16.9.4 RECENT DEVELOPMENT 233
16.10 EVOX THERAPEUTICS 234
16.10.1 COMPANY SNAPSHOT 234
16.10.2 PIPELINE PORTFOLIO 234
16.10.3 RECENT DEVELOPMENTS 235
16.11 JAZZ PHARMACEUTICALS, INC. 236
16.11.1 COMPANY SNAPSHOT 236
16.11.2 REVENUE ANALYSIS 236
16.11.3 PRODUCT PORTFOLIO 237
16.11.4 RECENT DEVELOPMENT 237
16.12 RENEURON GROUP PLC 238
16.12.1 COMPANY SNAPSHOT 238
16.12.2 REVENUE ANALYSIS 238
16.12.3 PRODUCT PORTFOLIO 239
16.12.4 RECENT DEVELOPMENT 239
16.13 UNITED THERAPEUTICS CORPORATION 240
16.13.1 COMPANY SNAPSHOT 240
16.13.2 REVENUE ANALYSIS 240
16.13.3 PRODUCT PORTFOLIO 241
16.13.4 RECENT DEVELOPMENT 241
17 QUESTIONNAIRE 242
18 RELATED REPORTS 245
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
